A statement released by the company today explains that their recent open share offer raised £6.6 million, while the rest has been conditionally raised by a share placing.
Peter George, executive chairman of Benchmark, commented: “We are pleased to have raised the full amount envisaged under the open offer. The proceeds of the open offer and placing will in part be used to scale up CleanTreat as we prepare to launch BMK08, our novel medicinal treatment to combat sea lice, one of the main biological challenges in salmon farming. We are excited about the opportunity we now have to deliver Benchmark's enormous potential."
The CleanTreat system has shown promising results in trials in Norway - where it has been used to treat over 30,000 tonnes of salmon - but it has not yet been approved for full scale commercial use.